Elevated blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in Parkinson's disease

NeuroToxicology

Volumn 40, Issue , 2014, Pages 52-56

  Louis, Elan D ^a,b,c,d   Michalec, Monika ^a   Jiang, Wendy ^e   Factor Litvak, Pam ^d   Zheng, Wei ^e  

^a Vagelos College of Physicians and Surgeons   (United States)

^b Department of Neurology College of Physicians and Surgeons Columbia University ^*  (United States)

^c Department of Medicine   (United States)

^d Department of Medicine   (United States)

^e PURDUE UNIVERSITY   (United States)

Author keywords

Beta carboline alkaloid; Environmental risk factors; Epidemiology; Harmane; Parkinson's disease

Indexed keywords

HARMAN; NEUROTOXIN;

AGE DISTRIBUTION; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CHEMICAL ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE MARKER; FAMILIAL DISEASE; FAMILY HISTORY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; NONPARAMETRIC TEST; PARKINSON DISEASE; PRIORITY JOURNAL; QUANTITATIVE STUDY; TOXIN ANALYSIS;

BETA-CARBOLINE ALKALOID; ENVIRONMENTAL RISK FACTORS; EPIDEMIOLOGY; HARMANE; PARKINSON'S DISEASE;

AGED; FEMALE; HARMINE; HUMANS; MALE; NEUROTOXINS; PARKINSON DISEASE; RISK FACTORS;

EID: 84890275887     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2013.11.005     Document Type: Article

References (41)

1. Albores R., Neafsey E.J., Drucker G., Fields J.Z., Collins M.A. Mitochondrial respiratory inhibition by N-methylated beta-carboline derivatives structurally resembling N-methyl-4-phenylpyridine. Proc Natl Acad Sci USA 1990, 87(23):9368-9372.
2. Anderson N.J., Tyacke R.J., Husbands S.M., Nutt D.J., Hudson A.L., Robinson E.S. In vitro and ex vivo distribution of [3H]harmane, an endogenous beta-carboline, in rat brain. Neuropharmacology 2006, 50(3):269-276.
3. Baldereschi M., Inzitari M., Vanni P., Di Carlo A., Inzitari D. Pesticide exposure might be a strong risk factor for Parkinson's disease. Ann Neurol 2008, 63(1):128.
4. Chaudhuri K.R., Buxton-Thomas M., Dhawan V., Peng R., Meilak C., Brooks D.J. Long duration asymmetrical postural tremor is likely to predict development of Parkinson's disease and not essential tremor: clinical follow up study of 13 cases. J Neurol Neurosurg Psychiatry 2005, 76(1):115-117.
5. Deng H., Gu S., Jankovic J. LINGO1 variants in essential tremor and Parkinson's disease. Acta Neurol Scand 2012, 125(1):1-7.
6. Dick FD. 2006. Parkinson's disease and pesticide exposures. Br Med Bull 79-80:219-231; doi:10.1093/bmb/ldl018.[Online 22 January 2007].
7. Fahn S., Elton E.R., UPDRS Development Committee Unified Parkinson's Disease Rating Scale. Recent Developments in Parkinson's Disease 1987, 153-163. Macmillan, Florham Park, NJ. S. Fahn, C.D. Marsden, D.B. Calne, M. Goldstein (Eds.).
8. Fuentes J.A., Longo V.G. An investigation on the central effects of harmine, harmaline and related beta-carbolines. Neuropharmacology 1971, 10(1):15-23.
9. Gatto N.M., Cockburn M., Bronstein J., Manthripragada A.D., Ritz B. Well-water consumption and Parkinson's disease in rural California. Environ Health Perspect 2009, 117(12):1912-1918.
10. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967, 17(5):427-442.
11. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55(3):181-184.
12. Jankovic J., McDermott M., Carter J., Gauthier S., Goetz C., Golbe L., et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990, 40(10):1529-1534.
13. Kuhn W., Müller T., Grosse H., Rommelspacher H. Plasma harman and norharman in Parkinson's disease. J Neural Transm Suppl 1995, 46:291-295.
14. Kuhn W., Müller T., Grosse H., Rommelspacher H. Elevated levels of harman and norharman in cerebrospinal fluid of parkinsonian patients. J Neural Transm 1996, 103(12):1435-1440.
15. Langston J.W., Langston E.B., Irwin I. MPTP-induced parkinsonism in human and non-human primates-clinical and experimental aspects. Acta Neurol Scand Suppl 1984, 100:49-54.
16. LaRoia H., Louis E.D. Association between essential tremor and other neurodegenerative diseases: what is the epidemiological evidence?. Neuroepidemiology 2011, 37(1):1-10.
17. Lewin L. Untersuchungen Uber Banisteria caapi Sp. Arch Exp Pathol Pharmacol 1928, 129:133-149.
18. Linn B.S., Linn M.W., Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968, 16(5):622-626.
19. Lorenc-Koci E., Rommelspacher H., Schulze G., Wernicke C., Kuter K., Smiałowska M., Wierońska J., Zieba B., Ossowska K. Parkinson's disease-like syndrome in rats induced by 2,9-dimethyl-beta-carbolinium ion, a beta-carboline occurring in the human brain. Behav Pharmacol 2006, 17(5-6):463-473.
20. Louis E.D., Benito-León J., Moreno-García S., Vega S., Romero J.P., Bermejo-Pareja F., et al. Blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentration in essential tremor cases in Spain. Neurotoxicology 2013, 34:264-268.
21. Louis E.D., Factor-Litvak P., Gerbin M., Jiang W., Zheng W. Blood harmane concentrations in 497 individuals relative to coffee, cigarettes, and food consumption on the morning of testing. J Toxicol 2011, 2011:628151.
22. Louis E.D., Jiang W., Pellegrino K.M., Rios E., Factor-Litvak P., Henchcliffe C., et al. Elevated blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in essential tremor. Neurotoxicology 2008, 29(2):294-300.
23. Louis E.D., Zheng W., Jurewicz E.C., Watner D., Chen J., Factor-Litvak P., et al. Elevation of blood beta-carboline alkaloids in essential tremor. Neurology 2002, 59(12):1940-1944.
24. Matsubara K., Collins M.A., Akane A., Ikebuchi J., Neafsey E.J., Kagawa M., et al. Potential bioactivated neurotoxicants, N-methylated beta-carbolinium ions, are present in human brain. Brain Res 1993, 610(1):90-96.
25. McKenna D.J. Plant hallucinogens: springboards for psychotherapeutic drug discovery. Behav Brain Res 1996, 73(1-2):109-116.
26. Minen M.T., Louis E.D. Emergence of Parkinson's disease in essential tremor: a study of the clinical correlates in 53 patients. Mov Disord 2008, 23(11):1602-1605.
27. Moncrieff J. Determination of pharmacological levels of harmane, harmine and harmaline in mammalian brain tissue, cerebrospinal fluid and plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogr 1989, 496(2):269-278.
28. Pfau W., Skog K. Exposure to beta-carbolines norharman and harman. J Chromatogr B Analyt Technol Biomed Life Sci 2004, 802(1):115-126.
29. Racette B.A., McGee-Minnich L., Moerlein S.M., Mink J.W., Videen T.O., Perlmutter J.S. Welding-related parkinsonism: clinical features, treatment, and pathophysiology. Neurology 2001, 56(1):8-13.
30. Ritz B., Yu F. Parkinson's disease mortality and pesticide exposure in California 1984-1994. Int J Epidemiol 2000, 29(2):323-329.
31. Rommelspacher H., Meier-Henco M., Smolka M., Kloft C. The levels of norharman are high enough after smoking to affect monoamineoxidase B in platelets. Eur J Pharmacol 2002, 441(1-2):115-125.
32. Rommelspacher H., Schmidt L.G., May T. Plasma norharman (beta-carboline) levels are elevated in chronic alcoholics. Alcohol Clin Exp Res 1991, 15(3):553-559.
33. Rybicki B.A., Johnson C.C., Uman J., Gorell J.M. Parkinson's disease mortality and the industrial use of heavy metals in Michigan. Mov Disord 1993, 8(1):87-92.
34. Semchuk K.M., Love E.J., Lee R.G. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 1992, 42(7):1328-1335.
35. Simões R.M., Constantino A., Gibadullina E., Houghton D., Louis E.D., Litvan I. Examining the motor phenotype of patients with both essential tremor and Parkinson's disease. Tremor Other Hyperkinet Mov (NY) 2012, 2. tre-02-47-149-3.
36. van der Mark M., Brouwer M., Kromhout H., Nijssen P., Huss A., Vermeulen R. Is pesticide use related to Parkinson disease? Some clues to heterogeneity in study results. Environ Health Perspect 2012, 120(3):340-347.
37. Vilariño-Güell C., Wider C., Ross O.A., Jasinska-Myga B., Kachergus J., Cobb S.A., et al. LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics 2010, 11(4):401-408.
38. Yahr M.D., Orosz D., Purohit D.P. Co-occurrence of essential tremor and Parkinson's disease: clinical study of a large kindred with autopsy findings. Parkinsonism Relat Disord 2003, 9(4):225-231.
39. Yang Y.J., Lee J.J., Jin C.M., Lim S.C., Lee M.K. Effects of harman and norharman on dopamine biosynthesis and l-DOPA-induced cytotoxicity in PC12 cells. Eur J Pharmacol 2008, 587(1-3):57-64.
40. Zetler G., Singbartl G., Schlosser L. Cerebral pharmacokinetics of tremor-producing harmala and iboga alkaloids. Pharmacology 1972, 7(4):237-248.
41. Zheng W., Wang S., Barnes L.F., Guan Y., Louis E.D. Determination of harmane and harmine in human blood using reversed-phased high-performance liquid chromatography and fluorescence detection. Anal Biochem 2000, 279(2):125-129.